Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedFeb 15, 2026
DataAggregated Company Financials
Companies21
  • 7D3.3%
  • 3M-3.7%
  • 1Y-39.7%
  • YTD-6.8%

Over the last 7 days, the Healthcare industry has risen 3.3%, driven by gains from Novo Nordisk of 5.1%. In contrast, the industry has lost 40% in the last 12 months. Looking forward, earnings are forecast to grow by 3.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 15 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b15.7x13.5x4.1x
Tue, 13 Jan 2026DKK 2.2tDKK 453.9bDKK 136.9b18x16x4.8x
Thu, 11 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.1x13.7x4.1x
Sat, 08 Nov 2025DKK 1.8tDKK 451.6bDKK 134.3b17.6x13.2x3.9x
Mon, 06 Oct 2025DKK 2.2tDKK 447.3bDKK 141.7b18.3x15.5x4.9x
Wed, 03 Sep 2025DKK 2.1tDKK 447.5bDKK 141.8b23.9x14.6x4.6x
Fri, 01 Aug 2025DKK 1.8tDKK 423.9bDKK 124.7b29.2x14.8x4.4x
Sun, 29 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Tue, 27 May 2025DKK 2.5tDKK 424.3bDKK 125.1b25.1x20x5.9x
Thu, 24 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.6x18.7x5.5x
Sat, 22 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.4x6.9x
Mon, 17 Feb 2025DKK 3.0tDKK 409.9bDKK 121.5b26.3x24.9x7.4x
Wed, 15 Jan 2025DKK 3.2tDKK 387.5bDKK 111.3b28.9x28.6x8.2x
Fri, 13 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.8x36.1x10.4x
Sun, 10 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Tue, 08 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.6x11.1x
Thu, 05 Sep 2024DKK 4.6tDKK 371.9bDKK 107.2b35.3x43.2x12.4x
Sat, 03 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b36.6x42x12.6x
Mon, 01 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b35.1x47.4x14.2x
Wed, 29 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.2x43.6x13x
Fri, 26 Apr 2024DKK 4.4tDKK 341.4bDKK 99.6b32.8x44.3x12.9x
Sun, 24 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Tue, 20 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.9x44.7x13x
Thu, 18 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42.1x11.8x
Sat, 16 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b32.9x38.7x10.9x
Mon, 13 Nov 2023DKK 3.6tDKK 319.8bDKK 89.9b31.7x39.6x11.1x
Wed, 11 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b34.2x41.7x11.2x
Fri, 08 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b36.3x43.3x11.6x
Sun, 06 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Tue, 04 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b39.7x39.3x10.3x
Thu, 01 Jun 2023DKK 3.1tDKK 287.2bDKK 75.5b41x40.6x10.7x
Sat, 29 Apr 2023DKK 3.1tDKK 272.6bDKK 69.0b44.7x45.1x11.4x
Mon, 27 Mar 2023DKK 2.9tDKK 291.2bDKK 69.0b36.7x42.1x10x
Wed, 22 Feb 2023DKK 2.8tDKK 289.4bDKK 68.9b40.5x40.8x9.7x
Price to Earnings Ratio

40.8x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 68.9bTotal Revenue: DKK 289.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.5x which is lower than its 3-year average PE of 33.0x.
  • The 3-year average PS ratio of 9.3x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.18%
Healthcare3.28%
Pharma4.82%
Healthcare Services3.64%
Biotech-2.38%
Medical Equipment-2.50%
Healthtech-4.06%
Life Sciences-5.84%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 356x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 24% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 310.605.1%
+DKK 66.9b		-44.3%PE13.5x
HLUN B H. LundbeckDKK 39.044.2%
+DKK 1.6b		-6.9%PE12.1x
EMBLA Embla Medical hfDKK 30.602.0%
+DKK 255.2m		-8.9%PE25x
BIOPOR BioPortoDKK 0.972.3%
+DKK 10.9m		-35.5%PS13.2x
SMSMED Scandinavian Medical SolutionsDKK 3.703.6%
+DKK 3.6m		-32.5%PE3957x

Latest News

NOVO B
DKK 310.60
Novo Nordisk
7D
5.1%
1Y
-44.3%
HLUN B
DKK 39.04
H. Lundbeck
7D
4.2%
1Y
-6.9%
CHEMM
DKK 403.40
ChemoMetec
7D
-6.6%
1Y
-29.5%
BIOPOR
DKK 0.97
BioPorto
7D
2.3%
1Y
-35.5%
DEMANT
DKK 176.20
Demant
7D
-6.0%
1Y
-32.9%
COLO B
DKK 488.60
Coloplast
7D
-1.0%
1Y
-38.7%

COLO B: Reset P/E And Dividend Will Support Future Upside

Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.
ALK B
DKK 212.00
ALK-Abelló
7D
-2.6%
1Y
36.8%

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins

Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.
ZEAL
DKK 399.70
Zealand Pharma
7D
-1.9%
1Y
-46.9%

ZEAL: Metabolic Collaboration Will Drive Future Upside As Profitability Assumptions Improve

Analysts have trimmed their price target for Zealand Pharma from €745.93 to €735.27, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that modestly adjust their overall valuation framework. What's in the News Zealand Pharma and OTR Therapeutics entered a multi program collaboration and license agreement focused on discovering and developing novel therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
EMBLA
DKK 30.60
Embla Medical hf
7D
2.0%
1Y
-8.9%

EMBLA: New Share Repurchase Program Will Support Upside Potential

Narrative Update on Embla Medical hf Analysts have modestly adjusted their price target for Embla Medical hf, keeping fair value steady at $37.40 while fine tuning assumptions such as a slightly higher discount rate, a marginally lower revenue growth outlook, a small reduction in expected profit margin, and a slightly higher future P/E. These changes reflect a more balanced view of risk and earnings potential.
AMBU B
DKK 82.40
Ambu
7D
-6.3%
1Y
-40.6%

AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook

The analyst price target for Ambu has been reduced from DKK 94.54 to DKK 78.00. This change reflects analysts’ updated assumptions on discount rate, revenue growth, profit margin and future P/E, as highlighted by recent Street research including a DKK 12 target cut.
GMAB
DKK 1,904.50
Genmab
7D
-2.7%
1Y
26.6%

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
SMSMED
DKK 3.70
Scandinavian Medical Solutions
7D
3.6%
1Y
-32.5%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
BRAINP
DKK 0.0034
Brain+
7D
70.0%
1Y
-94.8%
GUBRA
DKK 390.60
Gubra
7D
-5.0%
1Y
-41.2%
VIRO
DKK 12.30
ViroGates
7D
0.8%
1Y
11.8%
STENO
DKK 1.45
Stenocare
7D
5.5%
1Y
192.3%